Clearmind Medicine Business Summary

Clearmind Medicine Inc. (CMND) is a clinical-stage biotechnology firm specializing in the discovery and development of neuroplastogen-derived therapeutics for under-treated health conditions, primarily Alcohol Use Disorder (AUD). The company operates as a pre-revenue entity, funding its research and development through strategic capital raises and debt instruments, including a $2.5 million convertible note financing secured in February 2026. Its primary business segment is the clinical advancement of its intellectual property portfolio, which currently includes 19 patent families and its lead candidate, CMND-100, a non-hallucinogenic oral drug currently in Phase I/IIa trials. Within the competitive landscape, Clearmind sits alongside peers such as Cybin Inc., Entheon Biomedical, and Clairvoyant Therapeutics, distinguishing itself by focusing on non-hallucinogenic compounds that aim to eliminate the need for clinical supervision or adjunct psychotherapy. The company is led by CEO Dr. Adi Zuloff-Shani, a biomedical research veteran with over two decades of experience in healthcare leadership and the navigation of complex regulatory pathways for therapeutic commercialization. The executive team includes CFO Alan Rootenberg, who manages the firm's financial strategy and public market compliance, and Mark Haden, Vice President of Business Development, known for his extensive background in addiction-related clinical research. To bolster its North American presence, the firm recently appointed Mary-Elizabeth Gifford as Chief of Global Impact, focusing on U.S. regulatory advocacy and strategic alliances. Clearmind’s board is chaired by Amitay Weiss and includes notable directors such as Oz Adler, with institutional support from investors like L.I.A. Pure Capital Ltd.